# Oral Cannabidiol for Tobacco Cessation

> **NCT05445804** · PHASE1 · RECRUITING · sponsor: **Johns Hopkins University** · enrollment: 50 (estimated)

## Conditions studied

- Tobacco Use
- Tobacco Smoking
- Tobacco Dependence
- Tobacco Use Disorder
- Tobacco Use Cessation

## Interventions

- **DRUG:** 300 mg Cannabidiol
- **DRUG:** 600 mg Cannabidiol
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05445804
- **Lead sponsor:** Johns Hopkins University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-01
- **Primary completion:** 2026-12-01
- **Final completion:** 2027-02-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-01-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05445804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05445804, "Oral Cannabidiol for Tobacco Cessation". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05445804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*